The key focus of this survey will be to collect data on physicians awareness of the content of the Pradaxa® Prescriber Guide and the extent to which risk awareness is communicated to patients. The data collected with atrial fibrillation patients will show if and how well this information is received and understood.
Purpose:
Study Type
OBSERVATIONAL
Enrollment
1,213
Physician's Knowledge and Recommendations to Their Patients on Appropriate Dosing and Minimizing the Risk of Bleeding When Treated With Pradaxa® (Questionnaire)
The Outcome measure is summarized using the following categories; A: Physicians who spontaneously remembered the receipt of the Patient alert card, B: Physicians who spontaneously remembered the receipt of the Prescriber Guide, C: Physicians who were satisfied with the information provided in the Prescriber guide, D: Physicians who were aware of the importance of determining and controlling of the Patients renal function for correct pradaxa dosing. This Outcome measure is applicable only for the Physicians group.
Time frame: Day 1
Patient's Understanding of the Disease, Bleeding Signs, What to do in Case of Bleeding and How to Deal With Emergency Situations (Measuring Physician Compliance From Patient Perspective) (Questionnaire)
The Outcome measure is summarized using the following categories; A: Patients who received the Patient Alert Card, read it and understood its content, B: Patients who completed the Patient Alert Card with the patient specific information, C: Patients who were well informed about their treatment and the actions to be taken in case of serious complications, D: Patents who knew about the anticoagulant effect of Pradaxa®, E: Patients who were well aware of the potential side effect-bruising, F: Patients who were well aware of the potential side effect-bleeding. This Outcome measure is applicable only for the Patients group.
Time frame: Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Boehringer Ingelheim Investigational Site 81
Dobrich, Bulgaria
Boehringer Ingelheim Investigational Site 84
Gabrovo, Bulgaria
Boehringer Ingelheim Investigational Site 79
Montana, Bulgaria
Boehringer Ingelheim Investigational Site 85
Plovdiv, Bulgaria
Boehringer Ingelheim Investigational Site 80
Shumen, Bulgaria
Boehringer Ingelheim Investigational Site 86
Sliven, Bulgaria
Boehringer Ingelheim Investigational Site 87
Sofia, Bulgaria
Boehringer Ingelheim Investigational Site 88
Stara Zagora, Bulgaria
Boehringer Ingelheim Investigational Site 82
Varna, Bulgaria
Boehringer Ingelheim Investigational Site 83
Veliko Tarnovo, Bulgaria
...and 151 more locations